프로티나

468530KOSDAQ자연과학 및 공학 연구개발업

53.8 / 100

Reference Date: 2026-06-10

Financial Score14.5 / 40

News Sentiment21.3 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but PBR raises overvaluation concerns. Plunged 32.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

ProtiNA is a PPI big data company specializing in high-speed, large-scale analysis of protein-protein interactions (PPI) using its proprietary SPID platform. The SPID technology offers up to 100 times higher sensitivity than traditional methods and is applied in drug development, biomarker discovery, and antibody design. The company provides solutions like PPI PathFinder® and PPI Landscape® for pharmaceutical research.

Number of Employees

53people

Average Salary

70.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

13.55Industry Average 3.240.0Point

4.2x industry avg (risky)

ROE

-40.84Industry Average -32.093.5Point

In line with industry avg

Debt Ratio

5.62Industry Average 7.314.0Point

In line with industry avg

Trend 3.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

0.0 / 4

Detailed News Sentiment

5 totalPositive 5Neutral 0Negative 0Average Sentiment Score 85

Positive
프로티나, ADA 2026서 차세대 비만 치료제 전임상 데이터 공개
프로티나의 ADA 2026에서 GIPR 길항 항체 후보 PRT-1309의 긍정적 전임상 데이터 발표로 비만 치료제 개발에 대한 기대감 상승.
Positive
프로티나, EULAR서 PRT-101 경쟁력 입증…"차세대 골관절염 치...
프로티나의 PRT-101이 EULAR에서 임상 3상 경쟁 약물 대비 우수한 효능을 보여주며 글로벌 기술이전 가능성을 높였다.
Positive
프로티나, EULAR2026서 선두약물과 비교 데이터 발표
프로티나가 EULAR2026에서 PRT-101의 전임상 데이터를 공개하며 골관절염 치료제 개발에 대한 긍정적인 진전을 보여주었다.

Detailed Momentum

52-week position3.0Point

52w lower range (21%)

Current 34,850Won52-week high 111,80052-week low 13,800

1-month return0.0Point

1m -32.72% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15